Influenza Vaccine (Split Virion), lnactivated – Anflu®

Product Description

Influenza Vaccine (Split Virion), lnactivated – Anflu®
Pandemic Influenza Vaccine, lnactivated, Adjuvanted – Panflu®
H1N1 Influenza A Vaccine (Split Virion), lnactivated – Panflu.1®
Influenza Vaccine (Split Virion), lnactivated, Quadrivalent – TetrAnflu®

Anflu®, preservative-free trivalent influenza vaccine, was launched in 2006.

Panflu®, H5N1 flu vaccine, is the first of its kind in China and was approved for national stockpiling in 2008.

Panfu.1®, world's first H1N1 influenza A vaccine, was approved in 2009 and is used for massive inoculation around the world.

TetrAnflu®, quadrivalent influenza vaccine, was launched in 2020:

Provides complete coverage against all four types of influenza viruses and corresponding strains.

Demonstrates a low occurrence of adverse reactions and excellent safety.

Serum protection rates for each type are greater than 90%.

Sinovac Biotech Ltd.

  • CN
  • 2018
    On CPHI since
  • 2
    Certificates
  • 1000 - 4999
    Employees
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical
Clinical Research
Specifications
  • Selling Points
    Brand Name; Immune Health; International Approvals/Standards
  • Supplied from
    China

Sinovac Biotech Ltd.

  • CN
  • 2018
    On CPHI since
  • 2
    Certificates
  • 1000 - 4999
    Employees
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical
Clinical Research

More Products from Sinovac Biotech Ltd. (3)

Sinovac Biotech Ltd. resources (2)

  • News SINOVAC Named BogotáBio Exclusive Partner, Fueling New Vaccine Advances in Colombia

    Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced it has been named the exclusive strategic partner of BogotáBio, which will break ground as the first local human vaccine production facility to be established in Colombia’s capital city of Bogota.

  • Brochure SINOVAC Vaccines leaflets

    Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

    SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.